SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Schrodinger, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.12+0.52 (+2.30%)
Close on Oct 19, 2026
- Market cap
- $1.75B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$3.81 (+19.73%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Schrodinger, Inc. grew revenue 8.9% to $259.04M over the twelve months to Jun 30, 2026. Free cash flow was -$130.27M, down 634.5% from a year earlier.
Revenue
$259.04M
+8.9% vs. a year earlier
Operating income
-$153.45M
TTM Q2 2026
Free cash flow
-$130.27M
-634.5% vs. a year earlier
EPS, diluted
-$0.74
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.75B
- P/E ratio
- –
- Price to sales
- 6.76
- Price to book
- 5.33
- Dividend yield
- –
- Free cash flow yield
- -7.44%
Fundamentals
- Revenue
- $259.04M
- Net income
- -$54.34M
- EPS, diluted
- -$0.74
- Free cash flow
- -$130.27M
- Book value per share
- $4.34
- Diluted shares
- 76M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$259.04M+8.9% YoY
Gross profit
$147.31M+5.9% YoY
Operating income
-$153.45M
Net income
-$54.34M
EPS, diluted
-$0.74
Free cash flow
-$130.27M-634.5% YoY
Reported periodTrailing twelve months